Nature Cardiovascular Research

Nature Cardiovascular Research is an online-only monthly peer-reviewed journal of cardiac, vascular and blood biology published by Springer Nature within the Nature Portfolio, launched in January 2022 and with a 2025 Journal Impact Factor of 12.6（Nature Cardiovascular Research）是由（Springer Nature）在（Nature Portfolio）内出版的纯在线月刊同行评审期刊，聚焦心脏、血管与血液生物学，2022 年 1 月创刊，2025 年影响因子为 12.6。

Scope

• It covers fundamental, translational, clinical and public health research in cardiac, vascular and blood biology and haematology该刊涵盖心脏、血管与血液生物学及血液学的基础、转化、临床与公共卫生研究。
• It aims to advance understanding of the cardiovascular system and haematology during development and in health and disease, and to accelerate translation into clinics其目标在于推进对发育期、健康与疾病状态下心血管系统与血液学的理解，并加速向临床转化。^[1]
• Basic topics include development and angiogenesis, haematopoiesis, stem cell biology, physiology, metabolism, and genetics and genomics基础主题包括发育与血管新生、造血、干细胞生物学、生理学、代谢以及遗传学与基因组学。
• Disease topics include arrhythmia, cardiomyopathy, heart failure, valvular disease, ischaemic heart disease, hypertension, atherosclerosis, stroke, thrombosis, bleeding disorders and anaemia疾病主题包括心律失常、心肌病、心力衰竭、瓣膜病、缺血性心脏病、高血压、动脉粥样硬化、卒中、血栓形成、出血性疾病与贫血。^[2]
• Translational topics include diagnostic and prognostic tools and imaging, artificial intelligence, drug targeting, treatments of cardiovascular or blood diseases, and clinical trials转化主题包括诊断与预后工具与影像、人工智能、药物靶向、心血管或血液疾病的治疗以及临床试验。^[3]
• Health sciences topics include public and global health and public policy健康科学主题包括公共与全球卫生以及公共政策。
• Content types include original research Articles, Letters and Analyses, News and Views, Reviews, Perspectives, Comments, Features and Correspondence文章类型包括原创研究论文、通讯与分析、新闻与观点、综述、展望、评论、特写与通讯。

History

• It was launched in January 2022 by Springer Nature as one of three new Nature Portfolio journals that year, and its first volume appeared in 2022该刊于 2022 年 1 月由（Springer Nature）创刊，是当年新增的三本（Nature Portfolio）期刊之一，第 1 卷于 2022 年出版。
• It is an exclusively online publication that posts research articles as soon as they are ready该刊为纯在线出版，研究论文就绪后即在线发表。
• It is a transformative journal, offering authors an open access option alongside subscription publication该刊为转型期刊，在订阅出版之外为作者提供开放获取选项。
• It is published by Springer Nature in London and is indexed in the Emerging Sources Citation Index该刊由（Springer Nature）在伦敦出版，并被（Emerging Sources Citation Index）收录。
• It appears monthly with about twelve issues a year, and by 2026 it had reached volume 5该刊为月刊，每年约 12 期，至 2026 年已出版至第 5 卷。
• Its Journal Impact Factor moved from 10.8 in 2024 to 12.6 in 2025其影响因子由 2024 年的 10.8 提升至 2025 年的 12.6。

Editors

• Its Chief Editor is Vesna Todorovic, a molecular biologist based in the Nature Portfolio Berlin office其主编为（Vesna Todorovic），是驻（Nature Portfolio）柏林办公室的分子生物学家。
• Its Senior Editor Elisa Martini is based in the Milan office其资深编辑（Elisa Martini）驻米兰办公室。
• Its Senior Editor Andrea Tavosanis is also based in the Milan office其资深编辑（Andrea Tavosanis）亦驻米兰办公室。
• Its Associate Editor Cong Zhao is based in Shanghai其副编辑（Cong Zhao）驻上海。
• Unlike many journals, it has no external editorial board, and all editorial decisions are made by a team of full-time professional editors与许多期刊不同，该刊不设外部编委会，所有编辑决定均由一支全职专业编辑团队作出。
• General editorial enquiries go to the journal's editorial office through the address naturecvr@nature.com一般编辑事务通过（naturecvr@nature.com）与该刊编辑办公室联系。